Review



trk b inhibitor  (LKT Laboratories)


Bioz Verified Symbol LKT Laboratories is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 85

    Structured Review

    LKT Laboratories trk b inhibitor
    Trk B Inhibitor, supplied by LKT Laboratories, used in various techniques. Bioz Stars score: 85/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/k-252a/K252a/pmc03578719-38-6-9
    Average 85 stars, based on 6 article reviews
    trk b inhibitor - by Bioz Stars, 2026-10
    85/100 stars

    Images

    Related Articles

    Injection:

    Article Title: 4-Methylcatechol prevents derangements of brain-derived neurotrophic factor and TrkB-related signaling in anterior cingulate cortex in chronic pain with depression-like behavior
    Article Snippet: Chronic pain with mood disorder, resulting from a peripheral nerve injury, is a serious clinical problem affecting the quality of life.. A lack of brain-derived neurotrophic factor (BDNF) and abnormal intercellular signaling in the brain can mediate this symptom.. BDNF is induced in cultured neurons by 4-methylcatechol (4-MC), but little is known about its role in pain–emotion.

    Saline:

    Article Title: Neurotropin(®) ameliorates chronic pain via induction of brain-derived neurotrophic factor.
    Article Snippet: Neurotropin (NTP) , a non-protein extract isolated from the inflamed skin of rabbits inoculated with vaccinia virus, is used clinically for the treatment of neuropathic pain.. Moreover, NTP may activate the descending pain inhibitory system.. Depression-like behavior is often complicated by chronic pain.

    Article Title: 4-Methylcatechol prevents derangements of brain-derived neurotrophic factor and TrkB-related signaling in anterior cingulate cortex in chronic pain with depression-like behavior
    Article Snippet: Chronic pain with mood disorder, resulting from a peripheral nerve injury, is a serious clinical problem affecting the quality of life.. A lack of brain-derived neurotrophic factor (BDNF) and abnormal intercellular signaling in the brain can mediate this symptom.. BDNF is induced in cultured neurons by 4-methylcatechol (4-MC), but little is known about its role in pain–emotion.

    Article Title: Imipramine ameliorates pain-related negative emotion via induction of brain-derived neurotrophic factor.
    Article Snippet: Depression-like behavior is often complicated by chronic pain.. Antidepressants including imipramine (IMI) are widely used to treat chronic pain, but the mechanisms are not fully understood.. Brain-derived neurotrophic factor (BDNF) is a neuromodulator that reduces depression by regulating synaptic transmission.



    Similar Products

    95
    MedChemExpress k252a
    Suppression of the BDNF/TrkB signaling pathway by <t>K252a</t> can partly reverse the KCC2 downregulation and dysfunction after hypoxia injury. (A) NeuN and KCC2 immunolabeling in the hippocampal CA1 region of MCAO‐R mice, and those pretreated with K252a are depicted in confocal scanning images. Scale bars: 50 μm. (B) Quantitative assessment of membrane KCC2 labeling density in fluorescently labeled cells relative to NeuN (Sham: N = 4, MCAO‐R N = 7, MCAO‐ R + K252a: N = 7). (C) Confocal microscopy images illustrate KCC2 (green) and NeuN (blue‐violet) expression in cultured hippocampal neurons exposed to OGD/R with or without K252a. (Control: N = 23 cells; OGD/R: N = 21 cells; OGD/ R + K252a: N = 32 cells, all from N = 5 cultures). Scale bar: 5 μm. (D) Quantitative assessment of membrane KCC2 in cultured hippocampal neurons. (E) Experimental determination of E GABA recorded by a small‐tip whole‐cell patch clamp is depicted in I‐V plots. (F) Statistical analysis indicates a significant positive shift in E GABA after MCAO‐R, which is partially reversed by K252a (MCAO‐ R + K252a: −55.0 ± 4.2 mV, N = 3, n = 21 vs. MCAO‐R: −52.1 ± 3.8 mV, N = 3, n = 15, p = 0.08; MCAO‐ R + K252a vs. Sham: −57.5 ± 3.6 mV, N = 4, n = 19, p = 0.12). (G) Patch clamp recordings using a low‐chloride electrode solution demonstrate that both the amplitude (H) and frequency (I) of mIPSCs, which are KCC2‐dependent, are significantly reduced by MCAO‐R, with only the amplitude being partially rescued by pretreatment with K252a (MCAO‐R: 17.0 ± 3.4 pA, N = 3, n = 17 vs. MCAO‐ R + K252a:19.3 ± 2.8 pA, N = 3, n = 18, p = 0.13; MCAO‐R + K252a vs. Sham:21.3 ± 3.3 pA, N = 3, n = 15). * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the Sham group; ## p < 0.01 and ### p < 0.001 compared to the MCAO‐R group or OGD/R group.
    K252a, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/k-252a/K-252a/pmc12905008-59-7-12
    Average 95 stars, based on 1 article reviews
    k252a - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    93
    Tocris k252a
    Suppression of the BDNF/TrkB signaling pathway by <t>K252a</t> can partly reverse the KCC2 downregulation and dysfunction after hypoxia injury. (A) NeuN and KCC2 immunolabeling in the hippocampal CA1 region of MCAO‐R mice, and those pretreated with K252a are depicted in confocal scanning images. Scale bars: 50 μm. (B) Quantitative assessment of membrane KCC2 labeling density in fluorescently labeled cells relative to NeuN (Sham: N = 4, MCAO‐R N = 7, MCAO‐ R + K252a: N = 7). (C) Confocal microscopy images illustrate KCC2 (green) and NeuN (blue‐violet) expression in cultured hippocampal neurons exposed to OGD/R with or without K252a. (Control: N = 23 cells; OGD/R: N = 21 cells; OGD/ R + K252a: N = 32 cells, all from N = 5 cultures). Scale bar: 5 μm. (D) Quantitative assessment of membrane KCC2 in cultured hippocampal neurons. (E) Experimental determination of E GABA recorded by a small‐tip whole‐cell patch clamp is depicted in I‐V plots. (F) Statistical analysis indicates a significant positive shift in E GABA after MCAO‐R, which is partially reversed by K252a (MCAO‐ R + K252a: −55.0 ± 4.2 mV, N = 3, n = 21 vs. MCAO‐R: −52.1 ± 3.8 mV, N = 3, n = 15, p = 0.08; MCAO‐ R + K252a vs. Sham: −57.5 ± 3.6 mV, N = 4, n = 19, p = 0.12). (G) Patch clamp recordings using a low‐chloride electrode solution demonstrate that both the amplitude (H) and frequency (I) of mIPSCs, which are KCC2‐dependent, are significantly reduced by MCAO‐R, with only the amplitude being partially rescued by pretreatment with K252a (MCAO‐R: 17.0 ± 3.4 pA, N = 3, n = 17 vs. MCAO‐ R + K252a:19.3 ± 2.8 pA, N = 3, n = 18, p = 0.13; MCAO‐R + K252a vs. Sham:21.3 ± 3.3 pA, N = 3, n = 15). * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the Sham group; ## p < 0.01 and ### p < 0.001 compared to the MCAO‐R group or OGD/R group.
    K252a, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/k-252a/K+252a/pm41942002-57-9-22
    Average 93 stars, based on 1 article reviews
    k252a - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    95
    MedChemExpress agents k252a
    Suppression of the BDNF/TrkB signaling pathway by <t>K252a</t> can partly reverse the KCC2 downregulation and dysfunction after hypoxia injury. (A) NeuN and KCC2 immunolabeling in the hippocampal CA1 region of MCAO‐R mice, and those pretreated with K252a are depicted in confocal scanning images. Scale bars: 50 μm. (B) Quantitative assessment of membrane KCC2 labeling density in fluorescently labeled cells relative to NeuN (Sham: N = 4, MCAO‐R N = 7, MCAO‐ R + K252a: N = 7). (C) Confocal microscopy images illustrate KCC2 (green) and NeuN (blue‐violet) expression in cultured hippocampal neurons exposed to OGD/R with or without K252a. (Control: N = 23 cells; OGD/R: N = 21 cells; OGD/ R + K252a: N = 32 cells, all from N = 5 cultures). Scale bar: 5 μm. (D) Quantitative assessment of membrane KCC2 in cultured hippocampal neurons. (E) Experimental determination of E GABA recorded by a small‐tip whole‐cell patch clamp is depicted in I‐V plots. (F) Statistical analysis indicates a significant positive shift in E GABA after MCAO‐R, which is partially reversed by K252a (MCAO‐ R + K252a: −55.0 ± 4.2 mV, N = 3, n = 21 vs. MCAO‐R: −52.1 ± 3.8 mV, N = 3, n = 15, p = 0.08; MCAO‐ R + K252a vs. Sham: −57.5 ± 3.6 mV, N = 4, n = 19, p = 0.12). (G) Patch clamp recordings using a low‐chloride electrode solution demonstrate that both the amplitude (H) and frequency (I) of mIPSCs, which are KCC2‐dependent, are significantly reduced by MCAO‐R, with only the amplitude being partially rescued by pretreatment with K252a (MCAO‐R: 17.0 ± 3.4 pA, N = 3, n = 17 vs. MCAO‐ R + K252a:19.3 ± 2.8 pA, N = 3, n = 18, p = 0.13; MCAO‐R + K252a vs. Sham:21.3 ± 3.3 pA, N = 3, n = 15). * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the Sham group; ## p < 0.01 and ### p < 0.001 compared to the MCAO‐R group or OGD/R group.
    Agents K252a, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/k-252a/K-252a/pm41872517-54-2-16
    Average 95 stars, based on 1 article reviews
    agents k252a - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    95
    MedChemExpress k252a hy n6732
    Suppression of the BDNF/TrkB signaling pathway by <t>K252a</t> can partly reverse the KCC2 downregulation and dysfunction after hypoxia injury. (A) NeuN and KCC2 immunolabeling in the hippocampal CA1 region of MCAO‐R mice, and those pretreated with K252a are depicted in confocal scanning images. Scale bars: 50 μm. (B) Quantitative assessment of membrane KCC2 labeling density in fluorescently labeled cells relative to NeuN (Sham: N = 4, MCAO‐R N = 7, MCAO‐ R + K252a: N = 7). (C) Confocal microscopy images illustrate KCC2 (green) and NeuN (blue‐violet) expression in cultured hippocampal neurons exposed to OGD/R with or without K252a. (Control: N = 23 cells; OGD/R: N = 21 cells; OGD/ R + K252a: N = 32 cells, all from N = 5 cultures). Scale bar: 5 μm. (D) Quantitative assessment of membrane KCC2 in cultured hippocampal neurons. (E) Experimental determination of E GABA recorded by a small‐tip whole‐cell patch clamp is depicted in I‐V plots. (F) Statistical analysis indicates a significant positive shift in E GABA after MCAO‐R, which is partially reversed by K252a (MCAO‐ R + K252a: −55.0 ± 4.2 mV, N = 3, n = 21 vs. MCAO‐R: −52.1 ± 3.8 mV, N = 3, n = 15, p = 0.08; MCAO‐ R + K252a vs. Sham: −57.5 ± 3.6 mV, N = 4, n = 19, p = 0.12). (G) Patch clamp recordings using a low‐chloride electrode solution demonstrate that both the amplitude (H) and frequency (I) of mIPSCs, which are KCC2‐dependent, are significantly reduced by MCAO‐R, with only the amplitude being partially rescued by pretreatment with K252a (MCAO‐R: 17.0 ± 3.4 pA, N = 3, n = 17 vs. MCAO‐ R + K252a:19.3 ± 2.8 pA, N = 3, n = 18, p = 0.13; MCAO‐R + K252a vs. Sham:21.3 ± 3.3 pA, N = 3, n = 15). * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the Sham group; ## p < 0.01 and ### p < 0.001 compared to the MCAO‐R group or OGD/R group.
    K252a Hy N6732, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/k-252a/K-252a/10__1016_slash_j__jfutfo__2025__08__027-96-1-23
    Average 95 stars, based on 1 article reviews
    k252a hy n6732 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    Image Search Results


    Suppression of the BDNF/TrkB signaling pathway by K252a can partly reverse the KCC2 downregulation and dysfunction after hypoxia injury. (A) NeuN and KCC2 immunolabeling in the hippocampal CA1 region of MCAO‐R mice, and those pretreated with K252a are depicted in confocal scanning images. Scale bars: 50 μm. (B) Quantitative assessment of membrane KCC2 labeling density in fluorescently labeled cells relative to NeuN (Sham: N = 4, MCAO‐R N = 7, MCAO‐ R + K252a: N = 7). (C) Confocal microscopy images illustrate KCC2 (green) and NeuN (blue‐violet) expression in cultured hippocampal neurons exposed to OGD/R with or without K252a. (Control: N = 23 cells; OGD/R: N = 21 cells; OGD/ R + K252a: N = 32 cells, all from N = 5 cultures). Scale bar: 5 μm. (D) Quantitative assessment of membrane KCC2 in cultured hippocampal neurons. (E) Experimental determination of E GABA recorded by a small‐tip whole‐cell patch clamp is depicted in I‐V plots. (F) Statistical analysis indicates a significant positive shift in E GABA after MCAO‐R, which is partially reversed by K252a (MCAO‐ R + K252a: −55.0 ± 4.2 mV, N = 3, n = 21 vs. MCAO‐R: −52.1 ± 3.8 mV, N = 3, n = 15, p = 0.08; MCAO‐ R + K252a vs. Sham: −57.5 ± 3.6 mV, N = 4, n = 19, p = 0.12). (G) Patch clamp recordings using a low‐chloride electrode solution demonstrate that both the amplitude (H) and frequency (I) of mIPSCs, which are KCC2‐dependent, are significantly reduced by MCAO‐R, with only the amplitude being partially rescued by pretreatment with K252a (MCAO‐R: 17.0 ± 3.4 pA, N = 3, n = 17 vs. MCAO‐ R + K252a:19.3 ± 2.8 pA, N = 3, n = 18, p = 0.13; MCAO‐R + K252a vs. Sham:21.3 ± 3.3 pA, N = 3, n = 15). * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the Sham group; ## p < 0.01 and ### p < 0.001 compared to the MCAO‐R group or OGD/R group.

    Journal: CNS Neuroscience & Therapeutics

    Article Title: KCC2 Dysfunction Mediated by Microglial BDNF / TrkB Signaling Exacerbates Early Post‐Stroke Seizure Susceptibility

    doi: 10.1002/cns.70795

    Figure Lengend Snippet: Suppression of the BDNF/TrkB signaling pathway by K252a can partly reverse the KCC2 downregulation and dysfunction after hypoxia injury. (A) NeuN and KCC2 immunolabeling in the hippocampal CA1 region of MCAO‐R mice, and those pretreated with K252a are depicted in confocal scanning images. Scale bars: 50 μm. (B) Quantitative assessment of membrane KCC2 labeling density in fluorescently labeled cells relative to NeuN (Sham: N = 4, MCAO‐R N = 7, MCAO‐ R + K252a: N = 7). (C) Confocal microscopy images illustrate KCC2 (green) and NeuN (blue‐violet) expression in cultured hippocampal neurons exposed to OGD/R with or without K252a. (Control: N = 23 cells; OGD/R: N = 21 cells; OGD/ R + K252a: N = 32 cells, all from N = 5 cultures). Scale bar: 5 μm. (D) Quantitative assessment of membrane KCC2 in cultured hippocampal neurons. (E) Experimental determination of E GABA recorded by a small‐tip whole‐cell patch clamp is depicted in I‐V plots. (F) Statistical analysis indicates a significant positive shift in E GABA after MCAO‐R, which is partially reversed by K252a (MCAO‐ R + K252a: −55.0 ± 4.2 mV, N = 3, n = 21 vs. MCAO‐R: −52.1 ± 3.8 mV, N = 3, n = 15, p = 0.08; MCAO‐ R + K252a vs. Sham: −57.5 ± 3.6 mV, N = 4, n = 19, p = 0.12). (G) Patch clamp recordings using a low‐chloride electrode solution demonstrate that both the amplitude (H) and frequency (I) of mIPSCs, which are KCC2‐dependent, are significantly reduced by MCAO‐R, with only the amplitude being partially rescued by pretreatment with K252a (MCAO‐R: 17.0 ± 3.4 pA, N = 3, n = 17 vs. MCAO‐ R + K252a:19.3 ± 2.8 pA, N = 3, n = 18, p = 0.13; MCAO‐R + K252a vs. Sham:21.3 ± 3.3 pA, N = 3, n = 15). * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the Sham group; ## p < 0.01 and ### p < 0.001 compared to the MCAO‐R group or OGD/R group.

    Article Snippet: FUR was purchased from Sigma‐Aldrich, and minocycline, K252a, and CLP290 were from MedChemExpress.

    Techniques: Immunolabeling, Membrane, Labeling, Confocal Microscopy, Expressing, Cell Culture, Control, Patch Clamp

    Alleviating the severity of MCAO‐R‐induced seizures by blocking the BDNF/TrkB signaling and suppressing microglial activation. (A) Representative traces demonstrate the effective suppression of epileptiform burst firing induced by OGD/R in cultured hippocampal neurons by K252a. (B–D) Bar graphs present quantitative analysis, indicating that blocking the BDNF/TrkB signaling pathway with K252a significantly reduces the percentage of neurons exhibiting epileptiform bursting firing (B), the bursting frequency (C), and the total number of APs during 10 min (D) compared to control neurons (Control: N = 18 cells, OGD/R: N = 24 cells; FUR+OGD/R: N = 11 cells, all from N = 3 cultures). (E, F) Pretreatment with K252a or minocycline significantly decreases the occurrence of Racine IV‐V seizures at 40 mg/kg (E) and 50 mg/kg (F) cumulative PTZ dose. The distribution of seizure scores among mice is represented by the R2, R3, R4, and R5. (G‐H) Line charts reveal that K252a or minocycline reduced the percentage of MCAO‐R mice with Racine IV‐V seizures (G) and the average seizure score (H) at a cumulative PTZ dose of 40 and 50 mg/kg. (I) The cumulative PTZ dose required to induce epileptic behaviors with a Racine IV‐V is increased by blocking the BDNF/TrkB signaling pathway and suppressing microglial activation (Sham: N = 10, MCAO‐R: N = 13, MCAO‐ R + K252a: N = 11, MCAO‐R + Mino: N = 10). (J) Simplified schematic summarizing that MCAO‐R induces microglial activation (↑Iba1) and BDNF release, leading to TrkB activation, KCC2 downregulation, a depolarizing shift in E GABA and increased seizure risk, whereas minocycline and K252a act upstream at microglia and TrkB, respectively, to ameliorate this cascade. * p < 0.05 and ** p < 0.01 compared to the Sham group; # p < 0.05 and ## p < 0.01 compared to the MCAO‐R group.

    Journal: CNS Neuroscience & Therapeutics

    Article Title: KCC2 Dysfunction Mediated by Microglial BDNF / TrkB Signaling Exacerbates Early Post‐Stroke Seizure Susceptibility

    doi: 10.1002/cns.70795

    Figure Lengend Snippet: Alleviating the severity of MCAO‐R‐induced seizures by blocking the BDNF/TrkB signaling and suppressing microglial activation. (A) Representative traces demonstrate the effective suppression of epileptiform burst firing induced by OGD/R in cultured hippocampal neurons by K252a. (B–D) Bar graphs present quantitative analysis, indicating that blocking the BDNF/TrkB signaling pathway with K252a significantly reduces the percentage of neurons exhibiting epileptiform bursting firing (B), the bursting frequency (C), and the total number of APs during 10 min (D) compared to control neurons (Control: N = 18 cells, OGD/R: N = 24 cells; FUR+OGD/R: N = 11 cells, all from N = 3 cultures). (E, F) Pretreatment with K252a or minocycline significantly decreases the occurrence of Racine IV‐V seizures at 40 mg/kg (E) and 50 mg/kg (F) cumulative PTZ dose. The distribution of seizure scores among mice is represented by the R2, R3, R4, and R5. (G‐H) Line charts reveal that K252a or minocycline reduced the percentage of MCAO‐R mice with Racine IV‐V seizures (G) and the average seizure score (H) at a cumulative PTZ dose of 40 and 50 mg/kg. (I) The cumulative PTZ dose required to induce epileptic behaviors with a Racine IV‐V is increased by blocking the BDNF/TrkB signaling pathway and suppressing microglial activation (Sham: N = 10, MCAO‐R: N = 13, MCAO‐ R + K252a: N = 11, MCAO‐R + Mino: N = 10). (J) Simplified schematic summarizing that MCAO‐R induces microglial activation (↑Iba1) and BDNF release, leading to TrkB activation, KCC2 downregulation, a depolarizing shift in E GABA and increased seizure risk, whereas minocycline and K252a act upstream at microglia and TrkB, respectively, to ameliorate this cascade. * p < 0.05 and ** p < 0.01 compared to the Sham group; # p < 0.05 and ## p < 0.01 compared to the MCAO‐R group.

    Article Snippet: FUR was purchased from Sigma‐Aldrich, and minocycline, K252a, and CLP290 were from MedChemExpress.

    Techniques: Blocking Assay, Activation Assay, Cell Culture, Control